Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).

Study ID
NCT02173990

Study type
Interventional

Study phase
Phase 2

Study status
Terminated

Trial Acronym

PULSAR

Trial Summary

The PULSAR trial is an international, investigator-initiated, single arm open-label phase II study. The aim of this study is to measure the clinical activity of the combination FOLFIRI-aflibercept in an homogeneous group of patients with metastatic colorectal cancer, and treated with a FOLFIRI-aflibercept regimen as first line treatment.

More informations

Trial Starting Date

Jul 31,2014

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit